Effect of Ranolazine on Ischemic Myocardium IN Patients With Acute Cardiac Ischemia (RIMINI-Trial): A Randomized Controlled Pilot Trial.
Tjark F SchwemerLukas RadziwolekNavina DeutscherNadine DiermannSusanne SehnerStefan BlankenbergFelix Walter FriedrichPublished in: Journal of cardiovascular pharmacology and therapeutics (2018)
In conclusion, in this preliminary hypothesis-driven study, 6-week ranolazine therapy was shown to decrease the area of dyskinetic myocardium in patients with ACS by trend. Global strain rate measurement using speckle-tracking echocardiography can be applied measuring those effects and is, compared to other techniques, safe and harmless. Our data provide a sound basis for a follow-up trial.
Keyphrases
- phase iii
- study protocol
- left ventricular
- phase ii
- clinical trial
- cerebral palsy
- acute coronary syndrome
- computed tomography
- electronic health record
- randomized controlled trial
- big data
- stem cells
- heart failure
- placebo controlled
- ischemia reperfusion injury
- machine learning
- blood brain barrier
- double blind
- cerebral ischemia
- bone marrow
- artificial intelligence
- replacement therapy